#cardiosphere

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program

Capricor logo from website

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly?

Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse this week as pharma giant J&J severed ties with the…